Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22325264 | 0.87 | ALDH1A1 (0.44) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL22325340 | 0.83 | ALDH1A1 (0.34) | ALDH1A1LMNASMN1; SMN2RPS6KB1 | |
| SCHEMBL24262441 | 0.81 | LMNA (0.32) | LMNA | |
| SCHEMBL19858944 | 0.81 | ADORA2A (0.30) | — | |
| SCHEMBL28695251 | 0.74 | ALDH1A1 (0.33) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6033729 | 0.74 | NOS2 (0.44) | ALDH1A1LMNASMN1; SMN2RPS6KB1 | |
| SCHEMBL22325329 | 0.71 | ALDH1A1 (0.33) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL30338164 | 0.70 | LRRK2 (0.34) | RPS6KB1 | |
| SCHEMBL22325326 | 0.70 | LRRK2 (0.34) | RPS6KB1 | |
| SCHEMBL12776668 | 0.69 | ALDH1A1 (0.39) | ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325707-B2 | Process for preparing enantiomerically enriched JAK inhibitors | SUN PHARMACEUTICAL INDUSTRIES, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20240368166-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240300963-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2024-09-12 | — | — | US | disclosed |
| WO-2023018954-A1 | TREATMENT OF JAK-INHIBITION-RESPONSIVE DISORDERS WITH PRODRUGS OF JAK INHIBITORS | CONCERT PHARMACEUTICALS, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20220306636-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2022-09-29 | — | — | US | disclosed |
| US-20220213105-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220213105-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2022-07-07 | — | — | US | disclosed |
| CN-113906032-A | Methods for preparing enantiomerically enriched JAK inhibitors | 康塞特医药品有限公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-3921318-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | Concert Pharmaceuticals Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163653-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | CONCERT PHARMACEUTICALS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163653-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | CONCERT PHARMACEUTICALS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12325707-B2 | Process for preparing enantiomerically enriched JAK inhibitors | JAK1, JAK2, JAK3 | ALDH1A1 2401/4885LMNA 4673/4885SMN1; SMN2 4541/4885 |
| US-20220213105-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK2, JAK3 | ALDH1A1 2401/4885LMNA 4673/4885SMN1; SMN2 4541/4885 |
| US-20240300963-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK2, JAK3 | ALDH1A1 2401/4885LMNA 4673/4885SMN1; SMN2 4541/4885 |
| US-20240368166-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK2, JAK3 | ALDH1A1 2401/4885LMNA 4673/4885SMN1; SMN2 4541/4885 |
| US-20220306636-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK2, JAK3 | ALDH1A1 2401/4885LMNA 4673/4885SMN1; SMN2 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.